12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial

Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Bingfeng, Liu, Wu, Du, Juan, Liu, Hanyu, Zhao, Tianshuo, Yang, Shubo, Wang, Shuai, Zhang, Sihui, Liu, Bei, Liu, Yaqiong, Cui, Fuqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705985/
https://www.ncbi.nlm.nih.gov/pubmed/34960153
http://dx.doi.org/10.3390/vaccines9121407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705985/
https://www.ncbi.nlm.nih.gov/pubmed/34960153
http://dx.doi.org/10.3390/vaccines9121407

Ejemplares similares